The misregulation of reactive oxygen species (ROS) and transition metal ions contributes to the onset of Alzheimer’s Disease (AD). A series of new pyridinophane ligands with indole (L1 and L2) and 4-methyl-8-hydroxyquinoline (L3) modifications were evaluated as a means of targeting the molecular features of AD. These studies contribute to the overall understanding of the therapeutic potential of the pyridinophane backbone as a means of treating AD. In comparison to the parent molecule L4, the order of radical scavenging activity was determined to be L3 &gt; L4 ~ L2 &gt; L1, which is likely related to the reactivity and position of the substitutions. These results demonstrate that the addition of (1) the indole moiety to the pyridine, and (2) the addition of the 4-methyl-8-hydroxyquinoline moiety to the secondary amine on the tetra-aza macrocyclic pyridinophane both disrupt radical scavenging ability, warranting future exploration of these modifications in therapeutic design for AD.

Analysis of radical scavenging ability in modified small pyridine-containing ligands for therapeutic treatment of neurodegenerative diseases

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.